Contract notice
Section I: Contracting
authority
I.1) Name and addresses
NHS England
7&8 Wellington Place
Leeds
LS1 4AP
UK
Contact person: Stacey Thrower
E-mail: stacey.thrower@nhs.net
NUTS: UKE
Internet address(es)
Main address: https://www.england.nhs.uk//
Address of the buyer profile: https://www.england.nhs.uk//
I.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge at:
https://health-family.force.com/s/Welcome
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be sent electronically to:
https://health-family.force.com/s/Welcome
Tenders or requests to participate must be sent to the abovementioned address
Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at:
https://health-family.force.com/s/Welcome
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Provision of Community Pharmacy RSV and Pertussis Vaccination Enhanced Service
Reference number: AG24034
II.1.2) Main CPV code
85100000
II.1.3) Type of contract
Services
II.1.4) Short description
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHS England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy RSV and Pertussis Vaccination Enhanced Service within the Midlands Region.<br/><br/>Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:<br/><br/>• an adult programme (predominately to be commissioned through general practice); and<br/>• an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide additional capacity and increased access to supplement the core provision of these two programmes. <br/><br/>Pertussis (whooping cough) is a respiratory disease that is caused by the Bordetella pertussis bacterium. Pertussis can cause serious and life-threatening complications including pneumonia, difficulty in breathing (apnoea) and seizures. Pertussis most commonly affects infants, and very young infants are at highest risk of serious complications, of needing admission to hospital or of dying.<br/><br/>Pregnant women are eligible for the Pertussis vaccine from 16 weeks pregnancy, although the optimal window for protection is between 20 and 32 weeks of pregnancy. Commissioners have commissioned general practice and NHS trusts to deliver the Pertussis vaccination programme for pregnant women.<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide the Pertussis vaccination programme opportunistically to pregnant women to supplement the core service provision.<br/><br/>This Procurement Process is for the service provision in the Midlands Region where up to 66 sites from multiple potential Suppliers will be selected to provide the Services from May 2025. The 66 successful sites will be in three ICBs within the Midlands Region, with 22 sites allocated per lot to allow the Commissioner to ensure an even geographical spread. Should fewer than 22 sites be awarded to a Lot, up to 4 additional sites may be awarded under alternative Lot(s) at the Commissioners discretion. The ICB's included in this procurement are NHS Black Country ICB, NHS Leicester, Leicestershire, & Rutland ICB & NHS Birmingham and Solihull ICB.<br/><br/>The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV and pertussis vaccine to each eligible patient.<br/><br/>The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner’s control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.<br/><br/>Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.<br/><br/>Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on Friday 14th March 2025.
II.1.6) Information about lots
This contract is divided into lots:
Yes
Tenders may be submitted for all lots
II.2) Description
Lot No: 1
II.2.1) Title
Lot 1: NHS Black Country ICB
II.2.2) Additional CPV code(s)
85100000
II.2.3) Place of performance
NUTS code:
UKG
II.2.4) Description of the procurement
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHS England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy RSV and Pertussis Vaccination Enhanced Service within the Midlands Region.<br/><br/>Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:<br/><br/>• an adult programme (predominately to be commissioned through general practice); and<br/>• an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide additional capacity and increased access to supplement the core provision of these two programmes. <br/><br/>Pertussis (whooping cough) is a respiratory disease that is caused by the Bordetella pertussis bacterium. Pertussis can cause serious and life-threatening complications including pneumonia, difficulty in breathing (apnoea) and seizures. Pertussis most commonly affects infants, and very young infants are at highest risk of serious complications, of needing admission to hospital or of dying.<br/><br/>Pregnant women are eligible for the Pertussis vaccine from 16 weeks pregnancy, although the optimal window for protection is between 20 and 32 weeks of pregnancy. Commissioners have commissioned general practice and NHS trusts to deliver the Pertussis vaccination programme for pregnant women.<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide the Pertussis vaccination programme opportunistically to pregnant women to supplement the core service provision.<br/><br/>This Procurement Process is for the service provision in the Midlands Region where up to 66 sites from multiple potential Suppliers will be selected to provide the Services from May 2025. The 66 successful sites will be in three ICBs within the Midlands Region, with 22 sites allocated per lot to allow the Commissioner to ensure an even geographical spread. Should fewer than 22 sites be awarded to a Lot, up to 4 additional sites may be awarded under alternative Lot(s) at the Commissioners discretion. The ICB's included in this procurement are NHS Black Country ICB, NHS Leicester, Leicestershire, & Rutland ICB & NHS Birmingham and Solihull ICB.<br/><br/>The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV and pertussis vaccine to each eligible patient.<br/><br/>The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner’s control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.<br/><br/>Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.<br/><br/>The award criteria is as stated below:<br/><br/>Integration, collaboration and service sustainability - 20.00%<br/>Improving access, reducing health inequalities and facilitating choice - 45.00%<br/>Quality and Innovation - 25.00%<br/>Social Value - 10.00%<br/>Value - Pass / Fail<br/><br/>Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on Friday 14th March 2025.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/05/2025
End:
31/03/2029
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 2
II.2.1) Title
Lot 2: NHS Leicester, Leicestershire, & Rutland ICB
II.2.2) Additional CPV code(s)
85100000
II.2.3) Place of performance
NUTS code:
UKF2
II.2.4) Description of the procurement
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHS England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy RSV and Pertussis Vaccination Enhanced Service within the Midlands Region.<br/><br/>Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:<br/><br/>• an adult programme (predominately to be commissioned through general practice); and<br/>• an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide additional capacity and increased access to supplement the core provision of these two programmes. <br/><br/>Pertussis (whooping cough) is a respiratory disease that is caused by the Bordetella pertussis bacterium. Pertussis can cause serious and life-threatening complications including pneumonia, difficulty in breathing (apnoea) and seizures. Pertussis most commonly affects infants, and very young infants are at highest risk of serious complications, of needing admission to hospital or of dying.<br/><br/>Pregnant women are eligible for the Pertussis vaccine from 16 weeks pregnancy, although the optimal window for protection is between 20 and 32 weeks of pregnancy. Commissioners have commissioned general practice and NHS trusts to deliver the Pertussis vaccination programme for pregnant women.<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide the Pertussis vaccination programme opportunistically to pregnant women to supplement the core service provision.<br/><br/>This Procurement Process is for the service provision in the Midlands Region where up to 66 sites from multiple potential Suppliers will be selected to provide the Services from May 2025. The 66 successful sites will be in three ICBs within the Midlands Region, with 22 sites allocated per lot to allow the Commissioner to ensure an even geographical spread. Should fewer than 22 sites be awarded to a Lot, up to 4 additional sites may be awarded under alternative Lot(s) at the Commissioners discretion. The ICB's included in this procurement are NHS Black Country ICB, NHS Leicester, Leicestershire, & Rutland ICB & NHS Birmingham and Solihull ICB.<br/><br/>The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV and pertussis vaccine to each eligible patient.<br/><br/>The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner’s control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.<br/><br/>Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.<br/><br/>The award criteria is as stated below:<br/><br/>Integration, collaboration and service sustainability - 20.00%<br/>Improving access, reducing health inequalities and facilitating choice - 45.00%<br/>Quality and Innovation - 25.00%<br/>Social Value - 10.00%<br/>Value - Pass / Fail<br/><br/>Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on Friday 14th March 2025.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/05/2025
End:
31/03/2029
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 3
II.2.1) Title
Lot 3: NHS Birmingham and Solihull ICB
II.2.2) Additional CPV code(s)
85100000
II.2.3) Place of performance
NUTS code:
UKG3
II.2.4) Description of the procurement
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHS England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy RSV and Pertussis Vaccination Enhanced Service within the Midlands Region.<br/><br/>Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:<br/><br/>• an adult programme (predominately to be commissioned through general practice); and<br/>• an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide additional capacity and increased access to supplement the core provision of these two programmes. <br/><br/>Pertussis (whooping cough) is a respiratory disease that is caused by the Bordetella pertussis bacterium. Pertussis can cause serious and life-threatening complications including pneumonia, difficulty in breathing (apnoea) and seizures. Pertussis most commonly affects infants, and very young infants are at highest risk of serious complications, of needing admission to hospital or of dying.<br/><br/>Pregnant women are eligible for the Pertussis vaccine from 16 weeks pregnancy, although the optimal window for protection is between 20 and 32 weeks of pregnancy. Commissioners have commissioned general practice and NHS trusts to deliver the Pertussis vaccination programme for pregnant women.<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide the Pertussis vaccination programme opportunistically to pregnant women to supplement the core service provision.<br/><br/>This Procurement Process is for the service provision in the Midlands Region where up to 66 sites from multiple potential Suppliers will be selected to provide the Services from May 2025. The 66 successful sites will be in three ICBs within the Midlands Region, with 22 sites allocated per lot to allow the Commissioner to ensure an even geographical spread. Should fewer than 22 sites be awarded to a Lot, up to 4 additional sites may be awarded under alternative Lot(s) at the Commissioners discretion. The ICB's included in this procurement are NHS Black Country ICB, NHS Leicester, Leicestershire, & Rutland ICB & NHS Birmingham and Solihull ICB.<br/><br/>The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV and pertussis vaccine to each eligible patient.<br/><br/>The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner’s control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.<br/><br/>Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.<br/><br/>The award criteria is as stated below:<br/><br/>Integration, collaboration and service sustainability - 20.00%<br/>Improving access, reducing health inequalities and facilitating choice - 45.00%<br/>Quality and Innovation - 25.00%<br/>Social Value - 10.00%<br/>Value - Pass / Fail<br/><br/>Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on Friday 14th March 2025.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/05/2025
End:
31/03/2029
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section III: Legal, economic, financial and technical information
III.1) Conditions for participation
III.1.2) Economic and financial standing
Selection criteria as stated in the procurement documents
III.1.3) Technical and professional ability
Selection criteria as stated in the procurement documents
III.2) Conditions related to the contract
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.2) Time limit for receipt of tenders or requests to participate
Date:
14/03/2025
Local time: 12:00
IV.2.4) Languages in which tenders or requests to participate may be submitted
EN
IV.2.6) Minimum time frame during which the tenderer must maintain the tender
Duration in months: 6 (from the date stated for receipt of tender)
IV.2.7) Conditions for opening of tenders
Date:
14/03/2025
Local time: 13:00
Section VI: Complementary information
VI.1) Information about recurrence
This is a recurrent procurement:
No
VI.3) Additional information
This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.<br/><br/>The Contracting Authority will be using an eTendering system for this procurement exercise.<br/><br/>Further information and the ITT documentation can be found via the 'Live Opportunities' list on the e-tendering system at the following link:<br/><br/>https://health-family-contract-search.secure.force.com/?searchtype=Projects<br/><br/>You can also register your interest via this page. You can search for the opportunity by entering the following contract reference: C342898 - COMP: Community Pharmacy RSV and Pertussis Vaccination Enhanced Service<br/><br/>Neither the publication of this notice nor the employment of any particular terminology nor any other indication shall be taken to mean that the Contracting Authority intends to hold itself bound by any of the Regulations.<br/><br/>The award criteria is as stated below:<br/><br/>Integration, collaboration and service sustainability - 20.00%<br/>Improving access, reducing health inequalities and facilitating choice - 45.00%<br/>Quality and Innovation - 25.00%<br/>Social Value - 10.00%<br/>Value - Pass / Fail<br/><br/>Please see published procurement documentation for further details. All relevant information on the stages of evaluation are stated within the ITT documentation suite.
VI.4) Procedures for review
VI.4.1) Review body
NHS England
Wellington House, 133-135 Waterloo Rd
London
SE1 8UG
UK
Internet address(es)
URL: https://www.england.nhs.uk/
VI.4.2) Body responsible for mediation procedures
NHS Arden and GEM CSU
St John's House, East Street
Leicester
LE1 6NB
UK
Internet address(es)
URL: https://www.ardengemcsu.nhs.uk/
VI.5) Date of dispatch of this notice
03/03/2025